Established MRLs and Withdrawal Times Published for Dexamethasone

CgFARAD™ is proud to announce that decades of scientific persistence and collaboration have culminated in legal maximum residue limits (MRLs) and withdrawal times (WDTs) for dexamethasone now formally added to product labeling. What began years ago with a problem first identified by CgFARAD™ pharmacologist Dr. Trisha Dowling, an urgent gap in evidence‑based withdrawal guidance for dexamethasone, set in motion a research journey that gained momentum when CgFARAD™ Co‑Director Dr. Ron Johnson secured funding to investigate the issue. The results of the study are published in the Journal of Veterinary Pharmacology and Therapeutics September 2023.  This research, published with clear recommendations for WDTs, has now translated into regulatory action by Health Canada’s Veterinary Drugs Directorate, with pharmaceutical companies incorporating these validated withdrawal times directly into their labels. This milestone marks the successful completion of a long scientific and regulatory pathway, strengthening food safety and supporting veterinarians and producers across Canada.